99.28 0.00 (0.00%)
After hours: 5:18PM EDT
|Bid||99.31 x 1400|
|Ask||99.21 x 800|
|Day's Range||98.74 - 103.73|
|52 Week Range||92.56 - 141.86|
|Beta (3Y Monthly)||1.78|
|PE Ratio (TTM)||16.82|
|Earnings Date||Oct 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||152.26|
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.
Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.
Persistent de-emphasizing of tobacco is hurting growth, which should get reflected in the upcoming quarterly results of Walgreens Boots Alliance (WBA).
The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc's treatment for a second rare blood disorder, the company said. The treatment, Ultomiris, has already been approved in the United States, Japan and the European Union to treat adults with blood disorder called paroxysmal nocturnal hemoglobinuria. Friday's approval allows its use in treating atypical hemolytic uremic syndrome (aHUS), a condition that causes abnormal blood clots to form in small blood vessels in the kidneys, which could result in kidney failure.
Alexion Pharmaceuticals, Inc. (ALXN) today announced that the U.S. Food and Drug Administration (FDA) approved ULTOMIRIS® (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) for adult and pediatric (one month of age and older) patients. Atypical HUS is an ultra-rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to the walls of blood vessels and blood clots. Atypical HUS can cause sudden organ failure or a slow loss of function over time—potentially resulting in the need for a transplant, and in some cases, death.
NEW YORK , Oct. 18, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Achillion Pharmaceuticals, Inc. ("ACHN" ...
During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.
NEW YORK, Oct. 16, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Achillion Pharmaceuticals, Inc..
Alexion says it will acquire clinical-stage startup Achillion Pharmaceuticals Inc. for $930 million upfront.
Alexion Pharmaceuticals reached a deal to acquire Achillion for $930 million. The stocks were moving in opposite directions.
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO , Oct. 16, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) ...
Alexion Pharma (NASDAQ: ALXN ) will buy Achillion Pharma (NASDAQ: ACHN ) for the initial value of $930 million, or $6.30 per share in cash plus added contingent considerations for total potential value ...
Shares of Achillion Pharmaceuticals Inc. rocketed 82% in premarket trading Wednesday, after the biopharmaceutical company agreed to be acquired by Alexion Pharmaceuticals Inc. in a cash deal valued at $930 million. Alexion's stock slipped 0.1% ahead of the open. Under terms of the deal, Alexion will pay $6.30 for each Achillion share outstanding, which is 73% above Tuesday's closing price of $3.65 and implies a market-capitalization of $880.05 million. The deal also includes potential for an additional payment for Achillion shares in the form of contingent value rights (CVRs) to be paid if certain clinical and regulatory milestones are achieved. The CVRs include $1 a share for U.S. Food and Drug Administration approval of danicopan and $1 a share for ACH-5228 phase 3 initiation. Danicopan, Achillion's lead drug candidate, has received breakthrough therapy designation for treatment, in combination with a C5 monoclonal antibody, for patients with a rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH). Over the past three months, Achillion's stock has rallied 47.8% and Alexion shares have dropped 14.7%, while the iShares Nasdaq Biotechnology ETF has slipped 2.9% and the S&P 500 has eased 0.3%.
Alexion Pharmaceuticals Inc on Wednesday agreed to buy small biotech Achillion Pharmaceuticals Inc in a $930 million deal, to boost its pipeline of rare disease treatments. Alexion's offer of $6.30 per share represents a premium of 72.6% to Achillion stock's close on Tuesday.
Alexion Pharmaceuticals said Wednesday it reached an agreement to buy biopharmaceutical company Achillion Pharmaceuticals in a deal valued at $930 million. Alexion's offer of $6.30 a share cash is a 72.6% premium to Achillion's closing price of $3.65 on Tuesday. Alexion shares declined 1.33% to $103.42.